Developed for obesity to manage weight reduction and support long-term maintenance in conjunction with diet.
Mechanism of Action
Orlistat binds to gastric and pancreatic lipases in the lumen of the stomach and small intestine. This prevents these enzymes from hydrolyzing dietary fat into absorbable free fatty acids.
Route of Administration
Oral
Onset Time
24–48 hours
Duration
48–72 hours
Contraindications
Chronic malabsorption syndrome, Cholestasis, Hypersensitivity to orlistat, Pregnancy
Severe Adverse Events
Liver failure, Nephrolithiasis, Anaphylaxis — requires immediate medical attention
Information related to Orlistat is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
